ABSTRACT
We describe an in vitro test for detection of glial malignancies (GLI-M) based on enrichment and immunostaining of Circulating Glial Cells (CGCs) from peripheral blood sample. Extensive analytical validation studies using U87MG reference cell lines spiked into blood established the analytical performance characteristics of the test. The ability of the test to detect and differentiate GLI-M from non-malignant brain tumors (NBT), non glial type central nervous system (CNS) malignancies (NGCM), brain metastases from primary epithelial malignancies in other organs and healthy individuals were evaluated in four studies. The cumulative performance metrics of the test across all 4 clinical studies were 99.35% Sensitivity (95%CI: 96.44% - 99.98%) and 100% Specificity (95%CI: 99.37% - 100%). The performance characteristics of this test support its clinical utility for diagnostic triaging of individuals presenting with ICSOL.
Competing Interest Statement
Kevin O Neill, Nelofer Syed, Sudhir Dubey, Mahadev Potharaju, Sewanti Limaye, Anantbhushan Ranade, Giulio Anichini have declared no conflicts of interest. Timothy Crook declares financial interests in the form of fractional stock holding of the study sponsor. Vineet Datta is an employee of the study sponsor.
Funding Statement
This study did not receive any external funding. The entire study was funded by Datar Cancer Genetics Private Limited.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All biological samples were obtained from participants in three studies, GlioLENS with CTRI number CTRI/2019/02/017663 (http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31387), TRUEBLOOD with CTRI number CTRI/2019/03/017918 (http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31879) and RESOLUTE with CTRI number CTRI/2019/01/017219 (http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30733). Datar Cancer Genetics Limited Institutional Ethics Committee of Datar Cancer Genetics Private Limited gave ethical approval for GlioLENS, TRUEBLOOD and RESOLUTE. Institutional Ethics Committee, Clinical Studies of Apollo Hospitals, Hyderabad gave ethical approval for GlioLENS. All participants provided their written informed consent. All studies were performed in accordance with the Declaration of Helsinki. The Imperial College Ethics Committee / Institutional Review Board gave ethical approval for the prospective study conducted at Imperial College, London.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The details of the clinical studies in the Methods Section has been updated. The author list has been revised.
Data Availability
All data produced in the present work are contained in the manuscript and its supplementary file.
